Even with the recent developments in therapeutic approaches, including the introduction of potent new drugs targeting receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) inhibitors and immune checkpoint inhibitors, a substantial proportion of CRC patients experience relapse during the course of treatment [3]. Here, EGFR is linked to colorectal carcinoma.